Nano-enabled agglomerates and compact:Design aspects of challenges  

作　　者：Nazurah Binti Sazali Lai Wah Chan Tin Wui Wong 

机构地区：[1]Department of Pharmacy,Faculty of Science,National University of Singapore,Singapore 117543,Republic of Singapore [2]Non-Destructive Biomedical and Pharmaceutical Research Centre,Smart Manufacturing Research Institute,Universiti Teknologi MARA Selangor,Selangor 42300,Malaysia [3]Particle Design Research Group,Faculty of Pharmacy,Universiti Teknologi MARA Selangor 42300,Malaysia

出　　处：《Asian Journal of Pharmaceutical Sciences》2023年第2期28-48,共21页亚洲药物制剂科学（英文）

摘　　要：Nanoscale medicine confers passive and active targeting potential.The development of nanomedicine is however met with processing,handling and administration hurdles.Excessive solid nanoparticle aggregation and caking result in lowproduct yield,poor particle flowability and inefficient drug administration.These are overcome by converting the nanoparticles into a microscale dosage form via agglomeration or compaction techniques.Agglomeration and compaction nonetheless predispose the nanoparticles to risks of losing their nanogeometry,surface composition or chemistry being altered and negating biological performance.This study reviews risk factors faced during agglomeration and compaction that could result in these changes to nanoparticles.The potential risk factors pertain to materials choice in nanoparticle and microscale dosage form development,and their interplay effects with process temperature,physical forces and environmental stresses.To render the physicochemical and biological behaviour of the nanoparticles unaffected by agglomeration or compaction,modes to modulate the interplay effects of material and formulation with processing and environment variables are discussed.

关 键 词：AGGLOMERATION COMPACTION EXCIPIENT NANOMEDICINE NANOSTRUCTURE 

分 类 号：R318.08[医药卫生—生物医学工程] TB383.1[医药卫生—基础医学]